Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Allogene Therapeutics Inc
ALLO
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.25
-0.075
-5.64%
Últ. Act.: Oct 22, 1:47 PM
$1.32
-0.0139
-1.05%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Allogene Therapeutics Financials
Allogene Therapeutics (ALLO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Allogene Therapeutics Q2 EPS $(0.13) Beats $(0.17) Estimate, Sales $4.640M Beat $2.222K Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 43.48 percent increase over losses of $(0.23) per share
Benzinga Newsdesk
PRO
Allogene Therapeutics Q1 EPS $(0.18) Beats $(0.19) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 35.71 percent increase over losses of $(0.28) per share
Benzinga Newsdesk
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
Allogene Therapeutics Q4 EPS $(0.17) Beats $(0.22) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 21.66 percent. This is a 39.29 percent increase over losses of $(0.28) per share
Benzinga Newsdesk
Earnings Scheduled For March 12, 2026
Benzinga Insights
PRO
Allogene Therapeutics Q3 EPS $(0.19) Beats $(0.22) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 15.18 percent. This is a 40.63 percent increase over losses of $(0.32) per share
Benzinga Newsdesk
